A recent study, the first of its kind, reports an association between T1DM and AF, and between glycemic control and AF. Plus, there are interesting gender differences.
Payal Kohli, MD
Can tofoglifozin overcome patient adverse events to join the SGLT2 inhibitor market?
This quiz will help you better assess whether or not to prescribe an SGLT2 inhibitor for your type 2 diabetes patients.
The Food and Drug Administration (FDA) issued a formal communication warning about the risk of acidosis with the use of SGLT2 inhibitors.
Test your knowledge of recent findings in SGLT2 inhibitor efficacy and safety research.
Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.
What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?
Try your hand at this first in a series of questions on combination drug therapy to optimize treatment of T2DM.
Four questions for you to answer, four facts you need to know.